Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1584-1591

  Foley, Joseph W ^a   Bercury, Scott D ^a   Finn, Patrick ^a   Cheng, Seng H ^a   Scheule, Ronald K ^a   Ziegler, Robin J ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLISTATIN; GLUCAN 1,4 ALPHA GLUCOSIDASE; PARVOVIRUS VECTOR;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GLYCOGEN STORAGE DISEASE TYPE 2; GRIP STRENGTH; MOTOR PERFORMANCE; MOUSE; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE REGENERATION; MUSCLE STRENGTH; NONHUMAN; NUCLEOTIDE SEQUENCE; ROTAROD TEST; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 77956266764     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.110     Document Type: Article

References (44)

1. Hirschhorn, R and Reuser, AJJ (2001). Glycogen storage disease type ii: acid -glucosidase (acid maltase) deficiency. In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D (eds). The Metabolic and Molecular Bases of Inherited Disease, Vol.III. McGraw-Hill: New York, pp 3389-3420.
2. Kishnani, PS and Howell, RR (2004). Pompe disease in infants and children. J Pediatr 144(5 Suppl): S35-S43.
3. Raben, N, Nagaraju, K, Lee, E, Kessler, P, Byrne, B, Lee, L et al. (1998). Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092.
4. Fukuda, T, Ewan, L, Bauer, M, Mattaliano, RJ, Zaal, K, Ralston, E et al. (2006). Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 59: 700-708.
5. Raben, N, Takikita, S, Pittis, MG, Bembi, B, Marie, SK, Roberts, A et al. (2007). Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy 3: 546-552.
6. Ziegler, RJ, Bercury, SD, Fidler, J, Zhao, MA, Foley, J, Taksir, TV et al. (2008). Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alphaglucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 19: 609-621.
7. Bogdanovich, S, Krag, TO, Barton, ER, Morris, LD, Whittemore, LA, Ahima, RS et al. (2002). Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418-421.
8. Ohsawa, Y, Hagiwara, H, Nakatani, M, Yasue, A, Moriyama, K, Murakami, T et al. (2006). Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 116: 2924-2934.
9. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, et al.Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice, FASEB J, 22, 477-487
10. Qiao, C, Li, J, Jiang, J, Zhu, X, Wang, B, Li, J et al. (2008). Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19: 241-254.
11. Haidet, AM, Rizo, L, Handy, C, Umapathi, P, Eagle, A, Shilling, C et al. (2008). Long term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 105: 4318-4322.
12. Tsuchida, K (2008). Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol 27: 14-18.
13. Wagner, KR, Liu, X, Chang, X and Allen, RE (2005). Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA 102: 2519-2524.
14. Siriett, V, Salerno, MS, Berry, C, Nicholas, G, Bower, R, Kambadur, R et al. (2007). Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther 15: 1463-1470.
15. Whittemore, LA, Song, K, Li, X, Aghajanian, J, Davies, M, Girgenrath, S et al. (2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965-971.
16. Amthor, H, Nicholas, G, McKinnell, I, Kemp, CF, Sharma, M, Kambadur, R et al. (2004). Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol 270: 19-30.
17. Sidis, Y, Mukherjee, A, Keutmann, H, Delbaere, A, Sadatsuki, M and Schneyer, A (2006). Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147: 3586-3597.
18. Lee, SJ (2007). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2: e789.
19. Gilson, H, Schakman, O, Kalista, S, Lause, P, Tsuchida, K and Thissen, JP (2009). Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab 297: E157-E164.
20. Kota, J, Handy, CR, Haidet, AM, Montgomery, CL, Eagle, A, Rodino-Klapac, LR et al. (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 1: 6ra15.
21. Shimasaki, S, Koga, M, Esch, F, Cooksey, K, Mercado, M, Koba, A et al. (1988). Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA 85: 4218-4222.
22. Saito, S, Sidis, Y, Mukherjee, A, Xia, Y and Schneyer, A (2005). Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology 146: 5052-5062.
23. Pastore, L, Morral, N, Zhou, H, Garcia, R, Parks, RJ, Kochanek, S et al. (1999). Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 10: 1773-1781.
24. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356.
25. Ziegler, RJ, Lonning, SM, Armentano, D, Li, C, Souza, DW, Cherry, M et al. (2004). AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther 9: 231-240.
26. Franco, LM, Sun, B, Yang, X, Bird, A, Zhang, H, Schneider, A et al. (2005). Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12: 876-884.
27. Ziegler, RJ, Cherry, M, Barbon, CM, Li, C, Bercury, SD, Armentano, D et al. (2007). Correction of the biochemical and functional deficits in fabry mice following AAV8- mediated hepatic expression of alpha-galactosidase A. Mol Ther 15: 492-500.
28. Zhu, Y, Jiang, JL, Gumlaw, NK, Zhang, J, Bercury, SD, Ziegler, RJ et al. (2009). Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 17: 954-963.
29. Parsons, SA, Millay, DP, Sargent, MA, McNally, EM and Molkentin, JD (2006). Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 168: 1975-1985.
30. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease, J Pediatr., 2006, 149, 89-97
31. Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99-109.
32. Levine, JC, Kishnani, PS, Chen, YT, Herlong, JR and Li, JS (2008). Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 29: 1033-1042.
33. Nicolino, M, Byrne, B, Wraith, JE, Leslie, N, Mandel, H, Freyer, DR et al. (2009). Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11: 210-219.
34. van der Ploeg, AT, Clemens, P, Corzo, D, Lake, S, Skrinar, A, Escolar, D et al. (2008) Results from a randomized, double-blind, multicenter, multinational, placebocontrolled study of the safety and efficacy of Myozyme, recombinant human acid alpha-glucosidase (rhGAA), for the treatment of Pompe disease in juveniles and adults. Neurology 71: 155.
35. Winkel, LP, Van den Hout, JM, Kamphoven, JH, Disseldorp, JA, Remmerswaal, M, Arts, WF et al. (2004). Enzyme replacement therapy in late-onset Pompes disease: a three-year follow-up. Ann Neurol 55: 495-502.
36. van Capelle, CI, Winkel, LP, Hagemans, ML, Shapira, SK, Arts, WF, van Doorn, PA et al. (2008). Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18: 447-452.
37. Drost, MR, Hesselink, RP, Oomens, CW and van der Vusse, GJ (2005). Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 38: 1035-1043.
38. Amthor, H, Macharia, R, Navarrete, R, Schuelke, M, Brown, SC, Otto, A et al. (2007). Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 104: 1835-1840.
39. Cardone, M, Porto, C, Tarallo, A, Vicinanza, M, Rossi, B, Polishchuk, E et al. (2008). Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alphaglucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1: 6.
40. Winkel, LP, Kamphoven, JH, van den Hout, HJ, Severijnen, LA, van Doorn, PA, Reuser, AJ et al. (2003). Morphological changes in muscle tissue of patients with infantile Pompes disease receiving enzyme replacement therapy. Muscle Nerve 27: 743-751.
41. Thurberg, BL, Lynch Maloney, C, Vaccaro, C, Afonso, K, Tsai, AC, Bossen, E et al. (2006). Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86: 1208-1220.
42. Chu, Q, Moreland, R, Yew, NS, Foley, J, Ziegler, R and Scheule, RK (2008). Systemic Insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol Ther 16: 1400-1408.
43. Aoki, F and Kojima, I (2007). Therapeutic potential of follistatin to promote tissue regeneration and prevent tissue fibrosis. Endocr J 54: 849-854.
44. Sonoyama, K, Rutatip, S and Kasai, T (2000). Gene expression of activin, activin receptors, and follistatin in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 278: G89-G97.